Want to see SE:NEOLA full AI Analyst Report?
Top Page
Neola Medical AB
(NEOLA)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr0.59
▲(1.21% Upside)
Action:Reiterated
Date:09/09/26
The score is primarily held back by very weak financial performance (near-zero revenue, ongoing losses, and continued cash burn). Technicals add additional caution given the price remains below key longer-term moving averages. Valuation provides little support due to negative earnings and no dividend yield data, while no earnings-call or corporate-event information was available to offset these risks.
Positive Factors
Debt-free balance sheet
Zero reported debt limits financial risk and avoids interest or refinancing burdens, while substantial equity provides a financial buffer for continued product development. This flexibility can support commercialization efforts and reduce immediate solvency pressure as the company works toward revenue generation.
Negative Factors
No meaningful revenue yet
The absence of meaningful revenue indicates that Neola has not yet demonstrated commercial adoption or a functioning revenue engine. Until sales begin to scale, the company cannot validate market demand through financial performance or fund ongoing development from operating receipts.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt limits financial risk and avoids interest or refinancing burdens, while substantial equity provides a financial buffer for continued product development. This flexibility can support commercialization efforts and reduce immediate solvency pressure as the company works toward revenue generation.
Read all positive factors
Neola Medical AB (NEOLA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr59.11M
Dividend YieldN/A
Average Volume (3M)191.82K
Price to Earnings (P/E)―
Beta (1Y)-0.33
Revenue GrowthN/A
EPS Growth-13.49%
CountrySE
Employees9
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.11
Shares Outstanding110,476,940
10 Day Avg. Volume309,468
30 Day Avg. Volume191,823
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.07
Price to Sales (P/S)0.00
P/FCF Ratio-3.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr10.00M
Neola Medical AB Business Overview & Revenue Model
Company Description
Neola Medical AB (publ) specializes in developing advanced medical devices for the continuous pulmonary assessment of premature babies. At the core of its offerings is NEOLA, a sophisticated medical instrument critical for neonatal intensive care....
How the Company Makes Money
Neola Medical AB’s revenue model is primarily tied to commercializing its medical device(s) for neonatal monitoring, which would typically generate income through sales of devices to hospitals/clinics and potentially recurring revenue from associa...
Neola Medical AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
68
Positive
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 625.00K |
| Gross Profit | -1.39M | -1.53M | -1.43M | -571.00K | -7.36M |
| EBITDA | -9.75M | -8.54M | -7.58M | -9.82M | -6.64M |
| Net Income | -11.02M | -10.06M | -9.01M | -10.35M | -6.65M |
Balance Sheet | |||||
| Total Assets | 78.80M | 73.61M | 86.02M | 75.33M | 43.83M |
| Cash, Cash Equivalents and Short-Term Investments | 16.12M | 19.55M | 21.58M | 40.09M | 22.94M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.00M | 4.65M | 6.99M | 7.84M | 3.19M |
| Stockholders Equity | 75.80M | 68.96M | 79.03M | 67.48M | 40.63M |
Cash Flow | |||||
| Free Cash Flow | -21.25M | -10.84M | -18.85M | -20.05M | -17.45M |
| Operating Cash Flow | -11.95M | -10.84M | -6.54M | -8.50M | -6.93M |
| Investing Cash Flow | -9.34M | -11.18M | -12.30M | -11.56M | -10.52M |
| Financing Cash Flow | 17.86M | 20.00M | 336.00K | 37.20M | 23.74M |
Neola Medical AB Technical Analysis
Negative
0.58
Price Trends
0.60
Negative
0.81
Negative
0.86
Negative
Market Momentum
-0.01
Negative
43.95
Neutral
12.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NEOLA, the sentiment is Negative. The current price of 0.58 is above the 20-day moving average (MA) of 0.53, below the 50-day MA of 0.60, and below the 200-day MA of 0.86, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 43.95 is Neutral, neither overbought nor oversold. The STOCH value of 12.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NEOLA.
Neola Medical AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | kr1.06B | -27.98 | -3.99% | ― | -0.34% | 29.54% | |
52 Neutral | kr350.26M | -7.89 | -22.23% | ― | 6.49% | 25.03% | |
51 Neutral | kr555.45M | -66.67 | -2.84% | ― | -13.72% | 52.47% | |
44 Neutral | kr59.11M | -3.22 | ― | ― | ― | -13.49% | |
43 Neutral | kr509.38M | -4.44 | -37.43% | ― | 27.40% | 26.07% | |
43 Neutral | kr243.76M | -6.21 | -100.09% | ― | 65.82% | 41.28% |
* General Sector Average
SE:NEOLA
Neola Medical AB
0.53
-1.64
-75.73%
SE:SEZI
Senzime AB
3.16
-2.96
-48.36%
SE:BACTI.B
Bactiguard Holding AB
16.00
-9.80
-37.98%
SE:ACARIX
Acarix AB
0.21
-0.09
-29.90%
SE:BRAIN
BrainCool AB
0.92
0.05
5.89%
SE:SEDANA
Sedana Medical AB
10.00
-3.02
-23.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.